The US Food and Drug Administration has taken steps to curb the activities of unlicensed stem cell clinics while preparing for the roll-out in the autumn of a new regulatory framework for developers of cell and tissue-engineered products. ---Subscribe to MedNous to access this article--- Regenerative Medicine Regulation & Policy
